Priscilla Darwin APRN, FNP-C, MSCN

Cell 210-***-****

E-mail: adgmk2@r.postjobfree.com

EDUCATION

**** ******* ** *******- ****** Nurse Practitioner, University of Texas Medical Branch, Galveston, TX

2006 Bachelor of Science Degree in Nursing, University Of Texas Health Science Center San Antonio, TX

2004 Nursing Prerequisites, Austin Community College, Austin, TX

RELATED EXPERIENCE

2014 – Present Lead Nurse Practitioner, Department of Neurology, UTHSCSA, San Antonio, TX

2011 - 2013 Faculty/Family Nurse Practitioner, Department of OB/GYN, UNTHSC/JPS, Fort Worth, TX

2007 –2011 Registered Nurse, Department of OB/GYN, UTMB, Galveston, TX

2006 Registered Nurse & Patient Consultant, Aesthetic Enhancement, San Antonio, TX

Certifications

Basic Cardiac Life Support Exp. 2014

American Academy of Nurse Practitioners Exp. 2016

Multiple Sclerosis Certified Nurse June 2014

EDSS- Class B Sept 2014

Certification Rare Neuroimmunologic Disorders July 2016

Licensure

Advanced Practice Nurse in the State of Texas Exp. Dec 2019

Registered Nurse in the State of Texas Exp. Dec 2019

Continuing Education

Nov 2011 Staples Convention- Women’s Health Care: New Trends and Controversies

Apr 2011 Advanced Practice Education Associates

Oct 2011 Centering Pregnancy

Oct 2013 DMGCME

May 2014 Consortium of MS Centers Annual Meeting

May 2015 Consortium of MS Centers Annual Meeting

May 2017 Consortium of MS Centers Annual Meeting

April 2018 Annual Meeting – American Academy of Neurology

Awards and Professional Organizations

2017 Member of the AAN

2014 Member of the IOMSN

2014 Access to Care Committee Member- National MS Society

2012 Member of American Academy of Nurse Practitioners

2010 Scholarship Awarded: AENT

Teaching Experience

2014 Neuro Assessment and Lab, UTHSCSA NP Students

2016 Neurology grand rounds case presentation

Current Research (Sub- Investigator/ Study Coordinator)

A prospective study to identify the Impact of Dextromethorphan/Quinidine on CNS emotional lability scores in patients with Multiple Sclerosis

A Multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). Sponsor: Chugai. June 2014.

CFTY720D2311 A two-year, double-blind, randomized, multicenter, active-controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m once weekly in pediatric patients with multiple sclerosis. Sponsor: Novartis.

101MS408: A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod in Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects. Sponsor: Biogen, Idec.

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients. Sponsor: Genzyme.

A Longitudinal Study to Identify and Validate Biomarkers from Serum and Cerebrospinal Fluid in Patients Evaluated by Neurologist. Protocol AGS 1.0. Sponsor: Diogenix.

Contact this candidate